Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Kailian Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6195-3487; OpenAlex author ID A5085215903. Sources: OpenAlex.

Their work

Papers
25 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 3 papers · 2024: 2 papers · 2025: 7 papers · 2026: 5 papers

Papers 25

  1. Enhancing preoperative diagnosis of pancreatic ductal adenocarcinoma and mass-forming chronic pancreatitis: a study on normalized conventional MR imaging param… Last author DOI 10.1007/s00261-024-04652-7↗
  2. The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post-neoadjuvant therapy. Co-author DOI 10.1016/j.canlet.2026.218252↗
  3. Corrigendum to "The vulnerabilities of chemotherapy resistant pancreatic cancer revealed by organoids of pre- and post- neoadjuvant therapy" [Cancer Lett. (202… Co-author DOI 10.1016/j.canlet.2026.218298↗
  4. ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. Co-author DOI 10.1016/j.isci.2026.117479↗
  5. T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial. Co-author DOI 10.1016/j.ymthe.2026.03.012↗
  6. AI-powered vaccine breakthroughs: Targeting pancreatic cancer with neoantigens and combination therapies. Last author DOI 10.1016/j.bbcan.2025.189484↗
  7. Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac axis invasion: A safe and effective surgi… Co-author DOI 10.1016/j.surg.2024.109045↗
  8. A practical distribution pattern of α-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102282↗
  9. Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s41467-025-57520-3↗
  10. ODFormer: a Virtual Organoid for Predicting Personalized Therapeutic Responses in Pancreatic Cancer Co-author DOI 10.1101/2025.07.08.663664↗
  11. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. Co-author DOI 10.1172/jci.insight.181873↗
  12. Senescence-driven molecular subtyping in pancreatic cancer: a multi-omics framework for precision medicine. Co-author DOI 10.1186/s12885-025-15341-z↗
  13. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  14. Single-cell RNA sequencing reveals the process of CA19-9 production and dynamics of the immune microenvironment between CA19-9 (+) and CA19-9 (-) PDAC. Co-author DOI 10.1097/cm9.0000000000003130↗
  15. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Co-author DOI 10.1093/bjs/znac457↗
  16. A novel staging system derived from natural language processing of pathology reports to predict prognostic outcomes of pancreatic cancer: a retrospective cohor… Co-author DOI 10.1097/js9.0000000000000648↗
  17. Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resected Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-2856912/v1↗
  18. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. Co-author DOI 10.1016/j.ijsu.2022.106786↗
  19. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Co-author DOI 10.1038/s41467-022-29857-6↗
  20. LINC00483 promotes proliferation and metastasis through the miR-19a-3p/TBK1/MAPK axis in pancreatic ductal adenocarcinoma (PDAC). First author DOI 10.21037/atm-22-907↗
  21. The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients. Co-author DOI 10.3389/fonc.2021.717989↗
  22. OCIAD1 promoted pancreatic ductal adenocarcinoma migration by regulating ATM. First author DOI 10.1016/j.pan.2019.01.009↗
  23. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer. Co-author DOI 10.1096/fj.201800617r↗
  24. miRNA-1290 Promotes Aggressiveness in Pancreatic Ductal Adenocarcinoma by Targeting IKK1. Co-author DOI 10.1159/000495328↗
  25. miR-429 determines poor outcome and inhibits pancreatic ductal adenocarcinoma growth by targeting TBK1. First author DOI 10.1159/000373995↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Jin · 18 shared papers, 2015–2026 · strength 2.79
  2. Shiwei Guo · 15 shared papers, 2019–2026 · strength 2.43
  3. Xiaohan Shi · 14 shared papers, 2019–2026 · strength 2.35
  4. Suizhi Gao · 14 shared papers, 2019–2026 · strength 2.30
  5. Xiaoyi Yin · 11 shared papers, 2022–2026 · strength 1.97
  6. Xiongfei Xu · 10 shared papers, 2021–2026 · strength 1.69
  7. Lingyu Zhu · 6 shared papers, 2023–2026 · strength 1.08
  8. Yunguang Li · 6 shared papers, 2022–2026 · strength 1.06
  9. Guoxiao Zhang · 6 shared papers, 2021–2025 · strength 0.89
  10. Meilong Shi · 4 shared papers, 2025 · strength 0.77
  11. Bin Song · 6 shared papers, 2015–2025 · strength 0.76
  12. Dong Gao · 4 shared papers, 2022–2025 · strength 0.67
  13. Gang Li · 5 shared papers, 2015–2025 · strength 0.63
  14. Meilong Shi · 3 shared papers, 2026 · strength 0.59
  15. Bo Li · 4 shared papers, 2021–2023 · strength 0.54
  16. Gang Jin · 2 shared papers, 2025 · strength 0.53
  17. Shuo Shen · 4 shared papers, 2021–2023 · strength 0.52
  18. Yehan Zhang · 3 shared papers, 2022–2026 · strength 0.51
  19. Tianlin He · 2 shared papers, 2022–2026 · strength 0.48
  20. Huan Wang · 2 shared papers, 2026 · strength 0.47
  21. Zhuo Shao · 4 shared papers, 2019–2023 · strength 0.41
  22. Zhendong Fu · 2 shared papers, 2025 · strength 0.40
  23. Eric Tran · 2 shared papers, 2025–2026 · strength 0.39
  24. Yuxiao Li · 1 shared paper, 2026 · strength 0.36
  25. Gang Jin · 2 shared papers, 2022–2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.